BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181-188. [PMID: 15233698 DOI: 10.1111/j.1365-2036.2004.01999.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
2 Raha S, Mohanta D, Ahmaruzzaman M. Novel CuO/Mn3O4/ZnO nanocomposite with superior photocatalytic activity for removal of Rabeprazole from water. Sci Rep 2021;11:15187. [PMID: 34312406 DOI: 10.1038/s41598-021-94066-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
3 Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther. 2005;22 Suppl 3:39-44. [PMID: 16303036 DOI: 10.1111/j.1365-2036.2005.02711.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
4 Bautista JM. The rising trend of on-demand and intermittent proton pump inhibitor therapy in gastroesophageal reflux disease: What is the evidence? J Gastroenterol Hepatol 2006;21:S112-4. [DOI: 10.1111/j.1440-1746.2006.04713.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Scholten T, Dekkers CP, Schütze K, Körner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005;72:76-85. [PMID: 16113546 DOI: 10.1159/000087661] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
6 Chen L, Chen Y, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci Rep 2016;6:32126. [PMID: 27581096 DOI: 10.1038/srep32126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Reimer C, Bytzer P. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients. Alimentary Pharmacology & Therapeutics 2009;30:725-32. [DOI: 10.1111/j.1365-2036.2009.04092.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
8 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
9 Chung SJ, Kim SG, Jung HC, Song IS, Kim JS. [Clinical practice patterns of gastroenterologists for initial and maintenance therapy in gastroesophageal reflux disease: a nationwide online survey in Korea]. Korean J Gastroenterol. 2009;54:364-370. [PMID: 20026890 DOI: 10.4166/kjg.2009.54.6.364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
10 Locke GR 3rd. Current medical management of gastroesophageal reflux disease. Thorac Surg Clin 2005;15:369-75. [PMID: 16104127 DOI: 10.1016/j.thorsurg.2005.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Bixquert M. Maintenance therapy in gastro-oesophageal reflux disease. Drugs. 2005;65 Suppl 1:59-66. [PMID: 16335859 DOI: 10.1111/j.1365-2036.2007.03381.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
12 Fass R. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2012;10:338-345; quiz e39-40. [PMID: 22178462 DOI: 10.1016/j.cgh.2011.12.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
13 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Hughes DA, Marchetti M, Colombo G. Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. Expert Rev Pharmacoecon Outcomes Res 2005;5:29-38. [PMID: 19807558 DOI: 10.1586/14737167.5.1.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
15 Mohanta D, Raha S, Vikram Gupta S, Ahmaruzzaman M. Bioinspired green synthesis of engineered CuSnO3 quantum dots: An effective material for superior photocatalytic degradation of Rabeprazole. Materials Letters 2019;240:193-6. [DOI: 10.1016/j.matlet.2018.12.104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
16 Nagahara A, Hojo M, Asaoka D, Watanabe S. Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol 2010;3:61-8. [PMID: 26189996 DOI: 10.1007/s12328-010-0139-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 23.7] [Reference Citation Analysis]
18 Wu JC. Gastroesophageal reflux disease: an Asian perspective. J Gastroenterol Hepatol. 2008;23:1785-1793. [PMID: 19120871 DOI: 10.1111/j.1440-1746.2008.05684.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
19 Janssen W, Meier E, Gatz G, Pfaffenberger B. Effects of pantoprazole 20 mg in mildgastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term. Curr Ther Res Clin Exp 2005;66:345-63. [PMID: 24672134 DOI: 10.1016/j.curtheres.2005.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
20 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
21 Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20): 3091-3098 [PMID: 15918196 DOI: 10.3748/wjg.v11.i20.3091] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
22 Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:389-398. [PMID: 15298632 DOI: 10.1111/j.1365-2036.2004.02093.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
23 Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-224. [PMID: 21083596 DOI: 10.1111/j.1365-2036.2010.04508.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
24 Morgan DG, O'Mahony MF, O'Mahony WF, Roy J, Camacho F, Dinniwell J, Horbay GL, Husein-Bhabha FA; RAB-GRD-3002 Study Group. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can J Gastroenterol 2007;21:820-6. [PMID: 18080054 DOI: 10.1155/2007/203201] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
25 Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment Pharmacol Ther. 2007;25:511-517. [PMID: 17270007 DOI: 10.1111/j.1365-2036.2006.03196.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
26 Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005;21:1299-312. [DOI: 10.1111/j.1365-2036.2005.02490.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
27 Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol 2012; 18(19): 2390-2395 [PMID: 22654431 DOI: 10.3748/wjg.v18.i19.2390] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
28 Kaspari S, Kupcinskas L, Heinze H, Berghöfer P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005;17:935-41. [PMID: 16093871 DOI: 10.1097/00042737-200509000-00009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
29 Park JH, Park H, Lee DH, Sung IK. A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2013;19:219-26. [PMID: 23667753 DOI: 10.5056/jnm.2013.19.2.219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Goh K. "On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates? J Gastroenterol Hepatol 2006;21:S115-8. [DOI: 10.1111/j.1440-1746.2006.04714.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Khan Z, Alastal Y, Khan MA, Khan MS, Khalil B, Shrestha S, Kamal F, Nawras A, Howden CW. On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2018;2018:6417526. [PMID: 30158966 DOI: 10.1155/2018/6417526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wu JC, Lai LH, Chow DK, Wong GL, Sung JJ, Chan FK. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2011;23:155-160, e31. [PMID: 21087355 DOI: 10.1111/j.1365-2982.2010.01627.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
33 Nocon M, Labenz J, Jaspersen D, Meyer-sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study: LONG-TERM TREATMENT OF GERD PATIENTS. Alimentary Pharmacology & Therapeutics 2007;25:715-22. [DOI: 10.1111/j.1365-2036.2007.03249.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
34 Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, Pottie K, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev 2017;3:CD011969. [PMID: 28301676 DOI: 10.1002/14651858.CD011969.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
35 Pace F, Porro GB. On-demand PPI therapy in GERD. Curr Treat Options Gastroenterol 2008;11:35-42. [PMID: 21063862 DOI: 10.1007/s11938-008-0005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21:805-812. [PMID: 15801915 DOI: 10.1111/j.1365-2036.2005.02413.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
37 DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther. 2006;23 Suppl 1:33-39. [PMID: 16483268 DOI: 10.1111/j.1365-2036.2006.02798.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
38 Giannini EG, Savarino V, Testa R. Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease. Dig Dis Sci 2006;51:1602-6. [DOI: 10.1007/s10620-005-9035-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract 2013;2013:327571. [PMID: 24106498 DOI: 10.1155/2013/327571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MCJM, Kuipers EJ. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-85. [DOI: 10.1111/j.1365-2036.2006.02982.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 5.3] [Reference Citation Analysis]
41 Lee TJ, Fennerty MB, Howden CW. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease?: SYSTEMATIC REVIEW: PPI THERAPY IN GERD. Alimentary Pharmacology & Therapeutics 2004;20:1241-51. [DOI: 10.1111/j.1365-2036.2004.02289.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
43 Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, Ai MH, Wang J, Lv XG, Yang ZR, Dong WG. Proton pump inhibitor for non-erosive reflux disease: A meta-analysis. World J Gastroenterol 2013; 19(45): 8408-8419 [PMID: 24363534 DOI: 10.3748/wjg.v19.i45.8408] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
44 Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI. Am J Gastroenterol 2009;104:S27-32. [DOI: 10.1038/ajg.2009.49] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
45 Suzuki T, Matsushima M, Masui A, Tsuda S, Imai J, Nakamura J, Tsukune Y, Uchida T, Yuhara H, Igarashi M, Koike J, Mine T. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study. World J Gastroenterol 2015; 21(16): 5023-5031 [PMID: 25945018 DOI: 10.3748/wjg.v21.i16.5023] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
46 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006;62:685-91. [PMID: 16850327 DOI: 10.1007/s00228-006-0148-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
47 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:327571. [PMID: 24106498 DOI: org/10.1155/2013/327571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol. 2009;24:1326-1332. [PMID: 19702900 DOI: 10.1111/j.1440-1746.2009.05879.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
49 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
50 Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol. 2010;24:905-921. [PMID: 21126703 DOI: 10.1016/j.bpg.2010.09.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
51 Hughes DA, Bodger K, Bytzer P, de Herdt D, Dubois D. Economic Analysis of On-Demand Maintenance Therapy with Proton Pump Inhibitors in Patients with Non-Erosive Reflux Disease: . PharmacoEconomics 2005;23:1031-41. [DOI: 10.2165/00019053-200523100-00006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
52 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; ROSE Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol 2006;41:1132-40. [PMID: 16990197 DOI: 10.1080/00365520600615781] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
54 Leodolter A, Penagini R. On-demand therapy is a valid strategy in GERD patients: pros and cons. Dig Dis 2007;25:175-8. [PMID: 17827935 DOI: 10.1159/000103880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Bigard MA, Genestin E. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. Aliment Pharmacol Ther 2005;22:635-43. [PMID: 16181303 DOI: 10.1111/j.1365-2036.2005.02637.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
56 Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16:8-21. [PMID: 20535321 DOI: 10.5056/jnm.2010.16.1.8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 7.1] [Reference Citation Analysis]